Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | PLAU | P00749 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.55 |
| ▸ | TCF4 | P15884 | 1/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315174 | 0.94 | MAPT (0.80) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL5925553 | 0.88 | MAPT (0.72) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL2228992 | 0.87 | CA1 (0.62) | ALDH1A1TSHRKDM4EHPGDPOLB | |
| SCHEMBL15772389 | 0.86 | MAPT (0.70) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL6977966 | 0.86 | MAPT (0.70) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL25413790 | 0.86 | MAPT (0.70) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL1279147 | 0.86 | PLAU (0.72) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL21761420 | 0.86 | ALDH1A1 (0.69) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL1834055 | 0.84 | CA12 (0.71) | MAPTALDH1A1GAAHPGDPOLB | |
| SCHEMBL5037031 | 0.83 | MAPT (0.66) | MAPTALDH1A1TSHRSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904442-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2011-09-07 | — | — | EP | disclosed |
| US-8008296-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2322506-A1 | Histamine H3 receptor agents, preparation and therapeutic uses | Eli Lilly and Company (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-06-24 | — | — | US | disclosed |
| EP-1904442-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007005503-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | MAPT 825/4885ALDH1A1 2259/4885TSHR 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.